Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9049-9064

  Liu, Shuying ^a   Meng, Xiaolong ^a   Chen, Huiqin ^a   Liu, Wenbin ^a   Miller, Todd ^b,c   Murph, Mandi ^d   Lu, Yiling ^a   Zhang, Fan ^a   Gagea, Mihai ^a   Arteaga, Carlos L ^c   Mills, Gordon B ^a   Meric Bernstam, Funda ^a   González Angulo, Ana M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

Breast cancer; Dasatinib; Fulvestrant; MK0646; Targeting therapy

Indexed keywords

DALOTUZUMAB; DASATINIB; ESTROGEN RECEPTOR; FULVESTRANT; INSULIN RECEPTOR; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SIZE; CELL INVASION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FUNCTIONAL PROTEOMICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MIGRATION INHIBITION; MONOLAYER CULTURE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ACINAR CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DASATINIB; DRUG SYNERGISM; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910029848     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2022     Document Type: Article

References (40)

1. Jordan VC. The science of selective estrogen receptor modulators: concept to clinical practice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(17):5010-5013.
2. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-1717.
3. DeVita VT, Jr. and Rosenberg SA. Two hundred years of cancer research. The New England journal of medicine. 2012; 366(23):2207-2214.
4. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(3):509-518.
5. Wakeling AE, Dukes M and Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer research. 1991; 51(15):3867-3873.
6. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C and Dixon M. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer research. 2001; 61(18):6739-6746.
7. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T and Group AT. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359(9324):2131-2139.
8. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(11):2101-2109.
9. Petruzelka L and Zimovjanova M. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy-results from an expanded access programme. EJC Supplements. 2004; 2(3):132-133.
10. Ring A and Dowsett M. Mechanisms of tamoxifen resistance. Endocrine-related cancer. 2004; 11(4):643-658.
11. Cruz Jurado J, Richart Aznar P, Garcia Mata J, Fernandez Martinez R, Pelaez Fernandez I, Sampedro Gimeno T, Galve Calvo E, Murillo Jaso L, Polo Marques E and Garcia Palomo A. Management of patients with metastatic breast cancer. Advances in therapy. 2011; 28 Suppl 6:50-65.
12. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocrine-related cancer. 2005; 12 Suppl 1:S1-7.
13. Nicholson RI, Staka C, Boyns F, Hutcheson IR and Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-related cancer. 2004; 11(4):623-641.
14. Wilson CA and Slamon DJ. Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. Journal of the National Cancer Institute. 2005; 97(17):1238-1239.
15. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM and Nicholson RI. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast cancer research and treatment. 2006; 96(2):131-146.
16. Shin I, Miller T and Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(3 Pt 2):1008s-1012s.
17. Miller TW, Hennessy BT, Gonz, XE, Lez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garc, xEd, a E, xEd, a C, Shyr Y and Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. The Journal of Clinical Investigation. 2010; 120(7):2406-2413.
18. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer discovery. 2011; 1(4):338-351.
19. Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, Liu S, Gonzalez-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E and Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer research. 2011; 71(21):6773-6784.
20. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003; 144(3):1032-1044.
21. Dauvois S, White R and Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of cell science. 1993; 106 ( Pt 4):1377-1388.
22. Kansra S, Yamagata S, Sneade L, Foster L and Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Molecular and cellular endocrinology. 2005; 239(1-2):27-36.
23. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of medicinal chemistry. 2004; 47(27):6658-6661.
24. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP and Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England journal of medicine. 2006; 354(24):2531-2541.
25. Montero JC, Seoane S, Ocana A and Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(17):5546-5552.
26. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer cell. 2009; 15(6):539-550.
27. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D and Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther. 2007; 6(4):1414-1424.
28. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB and Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Molecular Cancer Therapeutics. 2006; 5(10):2512-2521.
29. Nautiyal J, Majumder P, Patel BB, Lee FY and Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer letters. 2009; 283(2):143-151.
30. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(19):6304-6312.
31. Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M and Saltz LB. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 2012; 118(19):4795-4800.
32. Lu W, Yamamoto V, Ortega B and Baltimore D. Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell. 2004; 119(1):97-108.
33. Cadigan KM and Liu YI. Wnt signaling: complexity at the surface. Journal of cell science. 2006; 119(Pt 3):395-402.
34. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? Journal of the National Cancer Institute. 2012; 104(13):975-981.
35. Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL and Kaufman PA. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. The lancet oncology. 2013; 14(3):228-235.
36. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang N-Y, Nishimura M, Greve J, Santell L, Zhang Y-W, Su Y, Kaufman DW, Billeci KL, Mai E, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences. 2013.
37. Muthuswamy SK, Li D, Lelievre S, Bissell MJ and Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nature cell biology. 2001; 3(9):785-792.
38. Gottardis MM, Robinson SP and Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. Journal of steroid biochemistry. 1988; 30(1-6):311-314.
39. Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, Giordano C, Bartella V, Casaburi I and Ando S. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer research. 2007; 67(7):3412-3421.
40. Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB and Fang X. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. The Journal of biological chemistry. 2004; 279(49):51075-51081.